Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TIL cell therapy in HIV positive patient with metastatic melanoma: case report.

Frontiers in oncology·2026
Same author

Appraising Treatment for Gastrointestinal Stromal Tumors of the Wild-Type Mutation in the Setting of NF1: A Case Report.

International journal of hematology-oncology and stem cell research·2025
Same author

Neoadjuvant Treatment Strategies in Gastrointestinal Stromal Tumors.

Hematology/oncology clinics of North America·2025
Same author

Contemporary Management of Merkel Cell Carcinoma.

Hematology/oncology clinics of North America·2025
Same author

Contemporary Management of Dermatofibrosarcoma Protuberans.

Hematology/oncology clinics of North America·2025
Same author

Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study.

EClinicalMedicine·2025

Related Experiment Video

Updated: Jan 11, 2026

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.4K

Contemporary Multimodal Management of Primary Retroperitoneal Sarcomas.

Rachel Hae-Soo Joung1, Jeffrey D Wayne2

  • 1Complex General Surgical Oncology Fellow, The University of Texas MD Anderson Cancer Center, 676 North St. Clair Street, Suite 2320, Chicago, IL 60611, USA.

Hematology/Oncology Clinics of North America
|November 12, 2025
PubMed
Summary

Retroperitoneal sarcoma treatment is challenging due to poor prognosis and surgical difficulties. Neoadjuvant radiotherapy shows promise for specific subtypes, with ongoing research into new therapies.

Keywords:
Adjuvant therapyMultidisciplinary approachNeoadjuvant therapyResectable primary retroperitoneal sarcomaRetroperitoneal sarcomaTargeted therapy

More Related Videos

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
12:34

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Published on: January 3, 2020

17.2K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.2K

Related Experiment Videos

Last Updated: Jan 11, 2026

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.4K
Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
12:34

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Published on: January 3, 2020

17.2K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.2K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Radiotherapy

Background:

  • Retroperitoneal sarcoma is a diverse group of cancers with a poor prognosis.
  • Complete surgical resection is difficult due to anatomical challenges.
  • Limited evidence exists for adjunctive treatments, often relying on data from other soft tissue sarcomas.

Purpose of the Study:

  • To review the current evidence on adjunctive treatment modalities for retroperitoneal sarcoma.
  • To highlight the potential benefits of neoadjuvant radiotherapy for specific subtypes.
  • To discuss ongoing research into novel therapeutic approaches.

Main Methods:

  • Literature review of studies on retroperitoneal sarcoma treatment.
  • Analysis of data on neoadjuvant radiotherapy outcomes.
  • Examination of ongoing clinical trials for novel therapies.

Main Results:

  • Neoadjuvant radiotherapy has demonstrated benefits in histologic subtypes with high locoregional recurrence rates.
  • Evidence for other adjunctive modalities remains sparse.
  • Several novel treatment strategies are under investigation.

Conclusions:

  • Achieving complete resection of retroperitoneal sarcoma is a significant challenge.
  • Neoadjuvant radiotherapy is a promising option for select patients.
  • Further research is crucial to develop effective adjunctive treatments for retroperitoneal sarcoma.